Skip to content
Clinical Trials – home

ANHYDROUS ROPIVACAINE HYDROCHLORIDE: A Patient's Guide to Local Anesthesia in Obstetric Care

1 / 1
trials open to patients / all trials
1+
Countries

In short

This article discusses a clinical trial investigating the use of Anhydrous Ropivacaine Hydrochloride, a local anesthetic, in combination with patient-controlled sedation for the repair of obstetric perineal lacerations. The study aims to improve patient comfort and experiences during this common postpartum procedure. We'll explore the trial's objectives, eligibility criteria, and potential benefits for new mothers undergoing perineal repair after childbirth.

At a glance

Study Drug
Anhydrous Ropivacaine Hydrochloride (local anesthetic)
Medical Condition
Obstetric perineal lacerations (grades I and II)
Main Objective
Investigate pain/discomfort and complications when adding patient-controlled sedation to standard pudendal nerve block
Study Design
Randomized controlled trial with two groups: control (pudendal nerve block only) and intervention (pudendal nerve block + PCS with propofol)
Primary Outcome
Pain/discomfort during the procedure
Key Secondary Outcomes
Preprocedural anxiety, repair time, skin-to-skin contact ability, time to micturition, patient experience
Inclusion Criteria
Adult patients (≥18 years), planned repair of grade I or II perineal laceration, informed consent
Key Exclusion Criteria
BMI > 35, preeclampsia, postpartum hemorrhage > 1000 ml, allergies to study medications, cognitive impairment

What is Ropivacaine?

Anhydrous Ropivacaine Hydrochloride, commonly known as Ropivacaine, is a local anesthetic medication. Local anesthetics are drugs that numb a specific area of the body, reducing pain sensations. Ropivacaine belongs to a class of medications called amide local anesthetics.

Medical Use in Obstetrics

Ropivacaine is primarily used in obstetric care, specifically for the repair of obstetric perineal lacerations. These are tears that can occur in the perineum (the area between the vagina and anus) during childbirth. The medication is used to provide pain relief during the repair of these tears.

How is Ropivacaine Administered?

In the context of repairing obstetric perineal lacerations, Ropivacaine is typically administered through a pudendal nerve block. This involves injecting the medication near the pudendal nerve, which provides sensation to the perineal area. The maximum daily dose is 100 mg, and it's usually given as a single treatment.

Current Clinical Trial

A clinical trial is currently being conducted to investigate the effectiveness of adding patient-controlled sedation with propofol to the standard Ropivacaine pudendal nerve block for repairing obstetric perineal lacerations. The main objective of this study is to assess patient pain/discomfort and complications when this combined approach is used.

Who Can Receive Ropivacaine in the Trial?

The trial has specific criteria for who can participate. Eligible participants include:

  • Adult patients (18 years or older)
  • Patients scheduled for examination and repair of grade I or II perineal lacerations
  • Patients who have given informed consent to participate in the study

However, certain conditions may exclude a patient from participating, such as:

  • BMI greater than 35
  • Preeclampsia or hypertensive disease
  • Postpartum hemorrhage greater than 1000 ml
  • Known or suspected allergy to any medication in the study
  • Functional disability in both hands that affects the ability to operate the patient-controlled sedation device
  • Cognitive impairment or language difficulties that make it hard to understand the study or operate the device
  • Perineal lacerations of grade III-IV

These criteria ensure the safety of participants and the reliability of the study results.

Potential Benefits

The use of Ropivacaine in repairing obstetric perineal lacerations may offer several potential benefits:

  • Reduced pain and discomfort during the repair procedure
  • Decreased anxiety before and during the procedure
  • Possibility of skin-to-skin contact with the baby during the repair
  • Potentially faster recovery and earlier mobilization after the procedure

These potential benefits are being studied in the current clinical trial to determine their extent and significance.

Important Considerations

While Ropivacaine is generally considered safe for its intended use, it's important to note:

  • As with any medication, there may be potential side effects or allergic reactions.
  • The effectiveness and patient experience may vary from person to person.
  • This medication should only be administered by trained healthcare professionals in appropriate medical settings.
  • Always inform your healthcare provider about any allergies, medical conditions, or medications you're taking before receiving any treatment.

Remember, the information provided here is based on a specific clinical trial and may not represent all possible uses or effects of Ropivacaine. Always consult with your healthcare provider for personalized medical advice.

Questions people often ask

Conditions where Anhydrous Ropivacaine Hydrochloride is being studied

Each condition opens its own overview and trial list

Trials with Anhydrous Ropivacaine Hydrochloride

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).